Lumea, a pioneer digital pathology company, will showcase its state-of-the-art solutions for prostate cancer at the upcoming 34th International Prostate Cancer Update in February. Event Details: The 34th International Prostate…
In the ever-evolving landscape of healthcare, breakthroughs in technology play a pivotal role in transforming patient outcomes. Lumea, a distinguished digital pathology company, is gearing up to showcase its cutting-edge…
Digital pathology is often publicized as being more efficient than traditional pathology, yet can that assertion survive scrutiny? It turns out that, as with many things, the answer is: maybe….
In this Ask a Pathologist Podcast episode, host James Thackeray speaks with Dr. Hillel Kahane, a board-certified uropathologist with over 30 years of experience, having personally signed out more than…
The cost of implementing digital pathology can vary widely depending on several factors, including the scale of the operation, the specific technology chosen, and the location and resources of the…
Related posts: Lumea BxChip® Now Available in European Markets New Digital Cancer Diagnostics Partnership Announced Between Lumea and Southern Utah University Lumea, AIRA Matrix, and Acupath have Partnered to Provide…
In the dynamic field of pathology, staying abreast of the latest advancements, breakthroughs, and networking opportunities is crucial for professionals seeking to excel in their careers. As we look ahead…
The speed of digital pathology compared to traditional pathology can vary depending on various factors, including the specific workflow, technology, and the proficiency of the individuals involved. If you are…
The accuracy of digital pathology compared to traditional pathology is not well studied, and some factors favor one over the other. Here are some things to keep in mind when…
“We’re all doctors. We all got into this field for a reason: the patient is central to everything we do. Using Lumea technology simply results in a better end product…
*BxLink has not been approved by the FDA for digital primary diagnosis. Refer to CAP guidelines regarding the use of digital pathology technologies.
